Hyaluronic acid (or sodium hyaluronate, SH) is a natural element of the human body that proves to be fundamental in the balance of the components of the extracellular matrix and in skin homeostasis, and it is involved in many biological processes such as collagen production, hydration, and cell regeneration of the skin.
The immediate reference that comes to mind when speaking of hyaluronic acid is about aesthetics medicine because of SH's high moisturizing properties, but it can also be used in other therapeutic areas including oral care, ophthalmology, and osteoarthritis. However, the shortcomings of this molecule limit its applications and development by pharmaceutical companies.
Today, thanks to its patented Hyaluromimethic® Technology, BMG Pharma is the only company that can develop a series of totally biocompatible biomaterials. This allows the maintenance of the natural endogenous SH in the body and reduces its degradation.
Thanks to its scientific and technological know-how BMG Pharma, a B2B biopharmaceutical company based in Italy in Milan with a plant in Torviscosa (UD) and operating in more than 80 countries in the world, develops products based on novel hyaluronic acid that are appreciated in the aesthetic dermatology area and are also useful for patients with degenerative joints, oral or ophthalmological problems. Products developed by BMG Pharma with the Hyaluromimetic® Technology can stimulate not only the production of collagen but also that of elastin and cell regeneration of irritated skin or inflamed joints and gums.
BMG Pharma is today the only company working directly on the hydroxylic molecular structure of hyaluronic acid, as raw material, as well as focusing on the formulation, topical or injectable, of the finished product.